Quinazoline ditosylate salt compounds
View Patent ↗Ditosylate salts of 4-quinazolineamines are described as well as methods of using the same in the treatment of disorde4rs characterized by aberrant erbB family PTK activity.
1. A compound of Formula (II),
or anhydrate or hydrate forms thereof.
2. The compound of claim 1 , wherein the compound is characterized by a powder x-ray diffraction pattern, comprising the peaks:
Two theta (deg)
d-spacing (angstroms)
4.8
18
8.7
10
18.0
4.9
18.9
4.7
21.0
4.2
22.3
4.0.
3. The compound of claim 1 , wherein the compound is characterized by a powder x-ray diffraction pattern, comprising the peaks:
Two theta (deg)
d-spacing (angstroms)
6.6
13
8.3
10
11.5
7.7
18.1
4.9
21.1
4.2.
4. A compound of Formula (II),
in anhydrate form.
5. A compound of Formula (II),
in monohydrate form.
6. A mixture of anhydrous and hydrate forms of a compound of Formula (II),
7. A pharmaceutical composition, comprising:
a therapeutically effective amount of a compound, or anhydrate or hydrate forms thereof, as claimed in claim 1 and one or m&re of pharmaceutically acceptable carriers, diluents and excipients.
8. A pharmaceutical composition, comprising:
a therapeutically effective amount of a compound, or anhydrate or hydrate forms thereof, as claimed in claim 4 and one or more of phamaceutically acceptable carriers, diluents and excipients.
9. A pharmaceutical composition, comprising:
a therapeutically effective amount of a compound, or anhydrate or hydrate forms thereof, as claimed in claim 5 and one or more of pharmaceutically acceptable carriers, diluents and excipients.
10. A pharmaceutical composition, comprising:
a therapeutically effective amount of the mixture, as claimed in claim 6 and one or more of pharmaceutically acceptable carriers, diluents and excipients.